Continuous Glucose Monitoring to Improve Metabolic Control in Patients With Diabetes Undergoing Peritoneal Dialysis at IMSS
Led by Coordinación de Investigación en Salud, Mexico · Updated on 2026-10-21
110
Participants Needed
2
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Patients with chronic kidney disease caused by type 2 diabetes often face metabolic challenges, including high blood sugar levels and related heart complications. Managing these problems is difficult during peritoneal dialysis because glucose from dialysis fluids affects insulin needs. This study aims to use continuous glucose monitoring to understand how different insulin types, doses, routes, and timing relate to blood sugar patterns, including high and low sugar episodes over 24-hour periods.
This observational study involves adults aged 40 to 70 with diabetic nephropathy who are insulin-dependent and have been on automated peritoneal dialysis for at least three months. Participants will wear a Guardian 3 glucose sensor placed under the skin on their non-dominant arm for two consecutive seven-day periods. Data is collected every five minutes and transmitted continuously to a connected smartphone app. On day 14, additional dialysis fluid measurements and dietary information will be collected along with insulin usage records.
Participants will be trained to use the glucose monitor and undergo blood tests for standard biochemical markers. Researchers will analyze glucose data to classify participants according to how much time their glucose levels remain within a target range. Statistical methods will identify associations between insulin regimens and glucose control. The study involves minimal risk, includes regular data audits, and participation lasts for 14 days with ongoing monitoring through the continuous glucose sensors.
CONDITIONS
Brief Title
Continuous Glucose Monitoring in Patients With Diabetes on Peritoneal Dialysis
Research Team
M
Miguel Angel Cuevas Budhart A Cuevas-Budhart, MSc, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Insulin-dependent diabetes mellitus requiring insulin for glycemic control.
At least three months of peritoneal dialysis treatment.
Age between 40 and 70 years.
Any sex.
You will not qualify if you...
Positive serology for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
Acute medical complications.
Hospitalization for cardiovascular, metabolic, or infectious conditions within the month preceding enrollment.
Cancer.
Pregnancy.
Allergy.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Continuous Glucose Monitoring Period
Duration - 14 days
Participants will wear a glucose sensor on their non-dominant arm for two consecutive seven-day periods to monitor blood sugar continuously. Blood samples, dietary information, and dialysis fluid will be collected to assess metabolic control and insulin effects.
1 initial visit, sensor placement; 1 sensor replacement visit on day 7; final assessment on day 14
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Early Detection of Type 2 Diabetes and Cardiovascular Risks Using CUORE and FINDRISC Tools in Adults Turning 50 in Marche Region
Comparing High Protein Egg White Pudding to Standard Supplements in Adults with Kidney Failure on Dialysis
Evaluating SugarVita 2.0 Digital Game for Supporting Self-Management in Adults with Type 2 Diabetes Over 12 Weeks
Study of AdiaVita Stem Cell and Glutathione Treatment for Adults with Chronic Kidney Disease
Study of How Bariatric Surgery Affects Fat Storage and Metabolic Health in Adults With or Without Type 2 Diabetes
AI-Based Analysis of Health Data to Predict Risk of Cardiovascular Disease, Type 2 Diabetes, Breast Cancer, Low Back Pain, and Osteoarthritis in Adults Aged 30 to 65
24-Week Randomized Trial of an AI-Designed Nutritional Supplement to Improve Blood Sugar Control in Adults with Type 2 Diabetes
Study of Alirocumab Given Every Two Weeks for 12 Weeks in Adults on Stable Hemodialysis or Peritoneal Dialysis
Supporting Adults With Type 2 Diabetes Using the EMPOWER Smartphone App, Health Coaching, and Community Programs
Evaluating App-based Motivational Interviewing and AI-Powered Support for Managing Type 2 Diabetes in Primary Care A Randomized Trial
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Subcutaneous versus intraperitoneal insulin for patients with diabetes mellitus on continuous ambulatory peritoneal dialysis: meta-analysis of non-randomized clinical trials.
Mussa H Almalki, Mansour A Altuwaijri, Mohammed S Almehthel...